(4S,11S,18S,25S)-4,11,18,25-tetra(propan-2-yl)-6-oxa-13,20-dithia-27-selena-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),7,12(31),14,19(30),21,26(29)-octaene-2,9,16,23-tetrone | 1451999-35-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: (4S,11S,18S,25S)-4,11,18,25-tetra(propan-2-yl)-6-oxa-13,20-dithia-27-selena-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),7,12(31),14,19(30),21,26(29)-octaene-2,9,16,23-tetrone
• CAS: 1451999-35-1
• 化学式: C₃₂H₄₀N₈O₅S₂Se
• 分子量: 759.812
• InChiKey: YAYLGMYWIOFNKQ-ZJZGAYNASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  48
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  238
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  (S)-2-(1-((tert-butoxycarbonyl)amino)-2-methylpropyl)-1,3-selenazole-4-carboxylic acid 、 (S)-2-[1-(tert-butoxycarbonylamino)-2-methylpropyl]thiazole-4-carboxylic acid 、 4-<2-<(S)-1-tert-butyloxycarbonylamino-2-methylpropyl>>-oxazole carboxylic acid 在 6-chloro-3-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazol-3-ium-1-olatehexafluorophosphate(V) 、 N,N-二异丙基乙胺 、 乙酸酐 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 (4S,11S,18S,25S)-4,11,18,25-tetra(propan-2-yl)-6-oxa-13,20-dithia-27-selena-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),7,12(31),14,19(30),21,26(29)-octaene-2,9,16,23-tetrone
  参考文献：
  名称：

  Synthesis of Azole-Enriched Cyclic Peptides by A Clean Solid-Phase-Based Cyclization-Cleavage Strategy

  摘要：

  Naturally occurring azole-enriched cyclic peptides have broad biological and pharmacological activities., Previous synthetic efforts have mainly concentrated on the preparation of individual target molecules in solution phase. A solid-phase-based cyclitive cleavage strategy was deployed here for efficient library synthesis of azole cyclopeptide derivatives, which is part of our continuous efforts for the characterization of potent modulators of multidrug resistance efflux proteins. Procedures were optimized to afford the azole cyclopeptides at high yield and purity, eliminating the need for any chromatographic purification steps. This development is ideal for high throughput library synthesis and screening and will facilitate the ultimate discovery of novel azole cyclopeptides with potent biological activities.

  DOI：

  10.1021/co400071y